Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNB-738 in Healthy Volunteers
NCT05215912Phase 1Completed
- Sponsor
- TeneoFour
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TNB-738 in Inflammatory Disorders, metabolic disorders and fibrosis (2 arms), sponsored by TeneoFour. Primary endpoints: Incidence of treatment emergent adverse events in Single Ascending group at 13 weeks, Incidence of treatment emergent adverse events in Multiple Ascending group at 21 weeks and 6 more. Started Apr 2022; status: completed.
02
Drugs
TNB-738
03
Conditions
Inflammatory Disordersmetabolic disordersfibrosis
Beyond the preview
Go deeper on NCT05215912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215912.